A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)
Conditions
Non-Small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only
Overall Status
Recruiting
Summary
This multicenter, retrospective and prospective observational, cohort study will examine the effect of second-line Tarceva treatment on long response in NSCLC patients with wild type or unknown EGFR status. Patients will be observed from the start of treatment for 8 months or until death. The extension of the retrospective versus prospective observation will depend on the lag between the date of the patient enrollment and the date of beginning of erlotinib therapy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients with stage IIIb or IV NSCLC

- Patients aged >/= 18 years

- Second-line treatment with Tarceva started before study inclusion and SD response, or CR/PR according to RECIST v. 1.1, lasting for at least 4 weeks

Exclusion Criteria:

- known presence of epidermal growth factor receptor (EGFR) mutation

- participation in a clinical trial with Tarceva during the study observation period
Locations
Chieti, Abruzzo, Italy
Status: Not yet recruiting
Pescara, Abruzzo, Italy
Status: Not yet recruiting
Cosenza, Calabria, Italy
Status: Not yet recruiting
Avellino, Campania, Italy
Status: Not yet recruiting
Napoli, Campania, Italy
Status: Not yet recruiting
Modena, Emilia-Romagna, Italy
Status: Not yet recruiting
Parma, Emilia-Romagna, Italy
Status: Not yet recruiting
Ravenna, Emilia-Romagna, Italy
Status: Not yet recruiting
Reggio Emilia, Emilia-Romagna, Italy
Status: Not yet recruiting
Roma, Lazio, Italy
Status: Not yet recruiting
Roma, Lazio, Italy
Status: Not yet recruiting
Roma, Lazio, Italy
Status: Not yet recruiting
Roma, Lazio, Italy
Status: Not yet recruiting
Roma, Lazio, Italy
Status: Not yet recruiting
Genova, Liguria, Italy
Status: Recruiting
Genova, Liguria, Italy
Status: Recruiting
Mantova, Lombardia, Italy
Status: Not yet recruiting
Milano, Lombardia, Italy
Status: Not yet recruiting
Monza, Lombardia, Italy
Status: Not yet recruiting
Macerata, Marche, Italy
Status: Not yet recruiting
Novara, Piemonte, Italy
Status: Not yet recruiting
Bari, Puglia, Italy
Status: Not yet recruiting
Lecce, Puglia, Italy
Status: Recruiting
San Giovanni Rotondo, Puglia, Italy
Status: Not yet recruiting
Cagliari, Sardegna, Italy
Status: Not yet recruiting
Catania, Sicilia, Italy
Status: Not yet recruiting
Palermo, Sicilia, Italy
Status: Not yet recruiting
Firenze, Toscana, Italy
Status: Not yet recruiting
Lido Di Camaiore, Toscana, Italy
Status: Not yet recruiting
Livorno, Toscana, Italy
Status: Recruiting
Pisa, Toscana, Italy
Status: Not yet recruiting
Bolzano, Trentino-Alto Adige, Italy
Status: Not yet recruiting
Perugia, Umbria, Italy
Status: Not yet recruiting
Padova, Veneto, Italy
Status: Not yet recruiting
Treviso, Veneto, Italy
Status: Not yet recruiting
Verona, Veneto, Italy
Status: Not yet recruiting
Start Date
April 2014
Completion Date
September 2015
Sponsors
Hoffmann-La Roche
Source
Hoffmann-La Roche
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page